首页> 外文OA文献 >Magnetic resonance imaging and histological studies on the behavior of a monomer stabilized superparamagnetic contrast medium for Magnetic Resonance Angiography in rat model
【2h】

Magnetic resonance imaging and histological studies on the behavior of a monomer stabilized superparamagnetic contrast medium for Magnetic Resonance Angiography in rat model

机译:磁共振成像和组织学研究的单体稳定型超顺磁性造影剂在大鼠模型中的行为

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to investigate a new, monomer-coated superparamagnetic contrast medium for magnetic resonance angiography. This was done by magnetic resonance imaging (MRI) and histologic examinations performed to characterize the contrast medium VSOP-C63 in the rat model. A total of 101 rats were examined to determine the optimal dose and the blood half-life as well as the distribution and degradation of the contrast medium in connection with a histopathologic evaluation.The MRI results obtained with a high-resolution 3D FLASH sequence showed a prolonged intravascular signal increase for all dosages (15, 30, 45, 60, 75 and 90 mmol/kg body mass (BM)) tested in 36 rats. The observed signal increase allowed for even delineating small, second- and third-order vessels. Blood half-lives were found to be dose-dependant. Significant differences in signal increase among the dosages tested were observed for doses up to 75 mmol/kg BM. The dose of 90 mmol/kg BM produced an overdose effect which was superimposed on the signal-enhancing effect at the early time points. With a time-optimized acquisition technique, bolus injection of VSOP-C63 at a dose of 45 mmol/kg produces the same signal-enhancing effect in the aorta as the injection of 0.2 mmol Gd/kg (Magnevistý). This is due to the favorable R2-to-R1 ratio of VSOP-C63, which is 1.3 as determined at 37°C in 0.9% NaCl using a field strength of 0.47 T.MRI and histologic examinations in 65 rats, among them 30 control animals, revealed differences in iron accumulation from the contrast medium between the liver and the spleen. The signal intensities determined using a proton-density-weighted SE sequence and a T2-weighted GRE sequence at 1.5 Tesla suggest that VSOP-C63 accumulates mainly in the liver and to a lesser extent in the spleen. Maximal iron accumulation after administration of the contrast medium is complete after 24 hours, when metabolization of the particles starts. Metabolization is different in the liver and the spleen. While traces of iron from the contrast medium can still be found in the liver after two months of continuous metabolization, the iron from the contrast medium completely disappears from the spleen within one week of contrast medium injection. At one and two months after contrast medium injection, renewed signal loss due to the beginning physiologic storage of the iron was observed. Iron determinations revealed no age dependence in the liver tissue of rats with a body mass of up to 500 g whereas the spleen showed a marked increase in the amount of physiologically stored iron with age. Examination of the control animals demonstrated that the signal intensities of the spleen changed with age. Animals with a body mass of 280 g or above, which corresponds to an age of about 55 days, showed large amounts of iron in the spleen. Animals below this limit displayed only slight to moderate physiologic iron storage. Since the body´s intrinsic iron stores, if they are large enough, likewise produce a signal reduction, the animals´ age must be taken into account when investigating superparamagnetic iron oxide particles. In contrast, age plays no role for liver imaging in the age group investigated in this study (up to a maximum of 500 g). The two MRI sequences used in this study showed similar characteristics in the liver and in the spleen with the more sensitive T2-weighted GRE sequence depicting a more pronounced signal loss. The precision of the proton-density-weighted SE sequence and the sensitivity of the T2-weighted GRE sequence together present a useful combination for determining the signal behavior of a contrast medium dose over time.The histologic examinations of the control animals demonstrated physiologic iron in the lungs and kidneys but not in the liver and the heart. Following contrast medium injection, iron oxide particles were taken up by the cells of the mononuclear phagocytosing system. This uptake was most pronounced in the liver, where iron was predominantly taken up by peripherolobular Kupffer´s cells. Only little contrast medium iron is taken up by the spleen but the signal loss produced is likewise pronounced due to the Spinell structure. The results suggest that in the course of metabolization of the contrast medium iron from the liver and spleen, there is an increase of iron storage in other organs, especially in the lungs and kidneys but to a lesser degree also in the heart. However, one must bear in mind that these organs also show physiologic iron storage with increasing age (Casale et al., 1981; Massie et al., 1983). The morphometric results (number of particles, surface, and particle size) show a highly positive correlation with the signal intensities at MRI as long as the contrast medium iron particles preserve their Spinell structure. The surface of the iron particles in the contrast medium animals increases one and two months after injection without any effect on the other parameters. This observation may be attributed to a different mode of storage resulting from redistribution of the iron. It may be speculated that individual particles within a cell fuse to form larger particles or a single large particle in the course of time.The MRI data in combination with the macroscopic and histopathologic findings show that the new contrast medium VSOP-C63 is a well-tolerated agent that is unlikely to produce any adverse reactions at a dose of 60 mmol Fe/kg BM. With its extended equilibrium phase and excellent imaging properties, VSOP-C63 is a promising candidate for MR angiography and represents an alternative to the agents currently used in clinical routine.
机译:本研究的目的是研究一种用于磁共振血管造影的新型单体涂层超顺磁性造影剂。这是通过磁共振成像(MRI)进行的,并进行了组织学检查以表征大鼠模型中的造影剂VSOP-C63。结合组织病理学评估,共检查了101只大鼠以确定最佳剂量和血液半衰期以及造影剂的分布和降解。高分辨率3D FLASH序列的MRI结果显示:在36只大鼠中测试的所有剂量(15、30、45、60、75和90 mmol / kg体重(BM))下,血管内信号延长的时间延长。观察到的信号增加甚至可以描绘出小型,二阶和三阶血管。发现血液半衰期是剂量依赖性的。对于高达75 mmol / kg BM的剂量,在所测试的剂量之间观察到信号增加的显着差异。 90 mmol / kg BM的剂量产生了过量的作用,在早期的时间点上叠加了信号增强作用。使用时间优化的采集技术,以45 mmol / kg的剂量大剂量注射VSOP-C63与在注射0.2 mmol Gd / kg时的主动脉产生相同的信号增强作用(Magnevistý)。这是由于VSOP-C63的R2与R1的有利比率,在0.4%T的场强下,在37%的0.9%NaCl中于37°C测得.1.3在动物中,肝脏和脾脏的造影剂显示出铁积累的差异。使用质子密度加权的SE序列和T2加权的GRE序列在1.5 Tesla处确定的信号强度表明VSOP-C63主要在肝脏中积累,而在脾脏中较少。当颗粒开始新陈代谢后,在服用对比剂后24小时内铁的最大积累就完成了。肝脏和脾脏的代谢不同。在连续代谢两个月后,肝脏中仍能发现来自造影剂的痕量铁,而在注射造影剂的一周内,来自脾脏的造影剂中的铁完全消失了。在注射造影剂后的一个月和两个月,观察到由于铁开始生理储存而导致的新信号丢失。铁含量的测定表明,体重不超过500 g的大鼠肝脏组织中没有年龄依赖性,而脾脏则显示随着年龄的增长,生理性铁含量显着增加。对照动物的检查表明,脾脏的信号强度随年龄而变化。体重为280 g或更高(对应于约55天的年龄)的动物的脾脏中显示大量铁。低于此限制的动物仅表现出轻微至中度的生理铁存储。由于人体固有的铁储备,如果足够大,同样会降低信号强度,因此在研究超顺磁性氧化铁颗粒时必须考虑动物的年龄。相反,在这项研究调查的年龄组(最大为500 g)中,年龄对肝脏成像没有影响。这项研究中使用的两个MRI序列在肝脏和脾脏中表现出相似的特征,其中T2加权GRE序列更敏感,表示信号丢失更为明显。质子密度加权的SE序列的精确度和T2加权的GRE序列的敏感性共同为确定造影剂剂量随时间变化的信号行为提供了有用的组合。对照动物的组织学检查显示生理铁肺和肾脏,但不在肝脏和心脏。注入造影剂后,单核吞噬细胞系统的细胞吸收了氧化铁颗粒。这种吸收在肝脏中最明显,肝脏主要是铁被周围小球的Kupffer细胞吸收。脾脏仅吸收很少的造影剂铁,但是由于Spinell结构,所产生的信号损失同样明显。结果表明,在从肝脏和脾脏中摄取造影剂铁的过程中,其他器官(尤其是肺和肾脏)中铁的存储量增加,但心脏中的铁存储量也较少。但是,必须牢记的是,这些器官还随着年龄的增长而显示出生理性的铁存储(Casale等,1981; Massie等,1983)。形态测量结果(颗粒数量,表面只要造影剂中的铁颗粒保持其Spinell结构,MRI信号强度就会与MRI信号高度相关。造影剂动物中的铁颗粒表面在注射后一个月和两个月增加,而对其他参数没有任何影响。该观察结果可归因于铁的重新分布所导致的不同的存储方式。可以推测,细胞内的单个颗粒会随着时间的流逝融合成较大的颗粒或单个大颗粒。MRI数据结合宏观和组织病理学发现表明,新型造影剂VSOP-C63是一种很好的造影剂,在60 mmol Fe / kg BM剂量下不太可能产生任何不良反应的耐受性药物。凭借其扩展的平衡相和出色的成像性能,VSOP-C63是MR血管造影术的有希望的候选者,并且代表了目前在临床常规治疗中使用的替代药物。

著录项

  • 作者

    Abramjuk Claudia;

  • 作者单位
  • 年度 2010
  • 总页数
  • 原文格式 PDF
  • 正文语种 deu
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号